TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.

Anne Constanze Regierer Rebecca Hasseli Martin Schaefer Bimba Franziska HoyerAndreas KrauseHanns-Martin LorenzAlexander PfeilJutta RichterTim SchmeiserHendrik Schulze-Koops Anja StrangfeldReinhard E VollChristof SpeckerUlf Mueller-Ladner

Published in: RMD open (2021)

General risk factors for severity of COVID-19 play a similar role in patients with RMDs as in the normal population. Influence of disease activity on COVID-19 outcome is of great importance as patients with high disease activity-even without glucocorticoids-have a worse outcome. Patients on TNFi show a better outcome of SARS-CoV-2 infection than patients on MTX. Immunosuppressants, rituximab and JAKi are associated with more severe course.

Keyphrases

disease activity
rheumatoid arthritis
systemic lupus erythematosus
end stage renal disease
rheumatoid arthritis patients
coronavirus disease
ejection fraction
sars cov
newly diagnosed
ankylosing spondylitis
diffuse large b cell lymphoma
respiratory syndrome coronavirus
patient reported outcomes
hodgkin lymphoma